%0 Journal Article
%T CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial
%A Feng Bi
%A Guoping Sun
%A Jianming Xu
%A Jin Li
%A Li Bai
%A Liwei Wang
%A Qiang Yao
%A Rongsheng Zheng
%A Shukui Qin
%A Wei Liu
%A Xiaohua Hu
%A Xiaohui He
%A Xuenong Ouyang
%A Yan Sun
%A Yi Luo
%A Yigui Chen
%A Ying Cheng
%A Yiping Zhang
%A Yuankai Shi
%A Yuhong Li
%A Yunpeng Liu
%A Zhehai Wang
%J Archive of "Cancer Communications".
%D 2019
%R 10.1186/s40880-019-0374-8
%X Eligible KRAS wild-type patients were identified at 38 hospitals in Chin
%K CMAB009
%K Cetuximab
%K Irinotecan
%K Second-line
%K mCRC
%K EGFR
%K KRAS
%K Immunogenicity
%K Fluoropyrimidine
%K Oxaliplatin failure
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534840/